Skip to content

Released May 13, 2025, after the close

10-Q filed May 13, 2025, 43 days after period end · 0000950170-25-070285

Q1 2025 · 10-Q
Revenue$1.63M−15.4% vs Q1 2024−12.4% vs Q4 2024
Net Income-$37.62MN/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.32N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$41,280,000N/M
Operating Cash Flow-$33,809,000N/M
Free Cash Flowderived-$35,005,000N/M
Margins · derived
Operating margin-2534.1%+118.8 pt vs Q1 2024
Net margin-2309.5%+184.3 pt vs Q1 2024

What the release said

The release

Same quarter

MetricQ1 2025Q1 2024Q1 2023Q1 2022
Revenue$1.63M$1.93M$58.98M$18.41M
Net Income-$37.62M-$48.00M-$18.88M-$65.69M
EPS Diluted-$0.32-$0.47-$0.19-$0.68

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR